These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 33596380)
1. Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. Nie S; Yao Y; Wu F; Wu X; Zhao J; Hua Y; Wu J; Huo T; Lin YL; Kneubehl AR; Vogt MB; Ferreon J; Rico-Hesse R; Song Y J Med Chem; 2021 Mar; 64(5):2777-2800. PubMed ID: 33596380 [TBL] [Abstract][Full Text] [Related]
2. Discovery, X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. Yao Y; Huo T; Lin YL; Nie S; Wu F; Hua Y; Wu J; Kneubehl AR; Vogt MB; Rico-Hesse R; Song Y J Am Chem Soc; 2019 May; 141(17):6832-6836. PubMed ID: 31017399 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, structure-activity relationship and antiviral activity of indole-containing inhibitors of Flavivirus NS2B-NS3 protease. Nie S; Zhao J; Wu X; Yao Y; Wu F; Lin YL; Li X; Kneubehl AR; Vogt MB; Rico-Hesse R; Song Y Eur J Med Chem; 2021 Dec; 225():113767. PubMed ID: 34450494 [TBL] [Abstract][Full Text] [Related]
4. Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases. Millies B; von Hammerstein F; Gellert A; Hammerschmidt S; Barthels F; Göppel U; Immerheiser M; Elgner F; Jung N; Basic M; Kersten C; Kiefer W; Bodem J; Hildt E; Windbergs M; Hellmich UA; Schirmeister T J Med Chem; 2019 Dec; 62(24):11359-11382. PubMed ID: 31769670 [TBL] [Abstract][Full Text] [Related]
5. Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses. Rut W; Groborz K; Zhang L; Modrzycka S; Poreba M; Hilgenfeld R; Drag M Antiviral Res; 2020 Mar; 175():104731. PubMed ID: 32014497 [TBL] [Abstract][Full Text] [Related]
6. The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection. Starvaggi J; Previti S; Zappalà M; Ettari R Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673962 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the Zika virus protease NS2B-NS3. Voss S; Nitsche C Bioorg Med Chem Lett; 2020 Mar; 30(5):126965. PubMed ID: 31980339 [TBL] [Abstract][Full Text] [Related]
8. Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses. Braun NJ; Quek JP; Huber S; Kouretova J; Rogge D; Lang-Henkel H; Cheong EZK; Chew BLA; Heine A; Luo D; Steinmetzer T ChemMedChem; 2020 Aug; 15(15):1439-1452. PubMed ID: 32501637 [TBL] [Abstract][Full Text] [Related]
10. Exploiting the unique features of Zika and Dengue proteases for inhibitor design. Majerová T; Novotný P; Krýsová E; Konvalinka J Biochimie; 2019 Nov; 166():132-141. PubMed ID: 31077760 [TBL] [Abstract][Full Text] [Related]
11. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094 [TBL] [Abstract][Full Text] [Related]
12. Methylene blue is a potent and broad-spectrum inhibitor against Zika virus Li Z; Lang Y; Sakamuru S; Samrat S; Trudeau N; Kuo L; Rugenstein N; Tharappel A; D'Brant L; Koetzner CA; Hu S; Zhang J; Huang R; Kramer LD; Butler D; Xia M; Li H Emerg Microbes Infect; 2020 Dec; 9(1):2404-2416. PubMed ID: 33078696 [TBL] [Abstract][Full Text] [Related]
13. Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Cavina L; Bouma MJ; Gironés D; Feiters MC Molecules; 2024 Aug; 29(17):. PubMed ID: 39274895 [TBL] [Abstract][Full Text] [Related]
14. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Lee H; Ren J; Nocadello S; Rice AJ; Ojeda I; Light S; Minasov G; Vargas J; Nagarathnam D; Anderson WF; Johnson ME Antiviral Res; 2017 Mar; 139():49-58. PubMed ID: 28034741 [TBL] [Abstract][Full Text] [Related]
15. NS2B-NS3 protease inhibitors as promising compounds in the development of antivirals against Zika virus: A systematic review. Nunes DAF; Santos FRDS; da Fonseca STD; de Lima WG; Nizer WSDC; Ferreira JMS; de Magalhães JC J Med Virol; 2022 Feb; 94(2):442-453. PubMed ID: 34636434 [TBL] [Abstract][Full Text] [Related]
16. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review. Wahaab A; Mustafa BE; Hameed M; Stevenson NJ; Anwar MN; Liu K; Wei J; Qiu Y; Ma Z Viruses; 2021 Dec; 14(1):. PubMed ID: 35062249 [TBL] [Abstract][Full Text] [Related]
17. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. Zephyr J; Rao DN; Johnson C; Shaqra AM; Nalivaika EA; Jordan A; Kurt Yilmaz N; Ali A; Schiffer CA Bioorg Chem; 2023 Feb; 131():106269. PubMed ID: 36446201 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase. Sidique S; Shiryaev SA; Ratnikov BI; Herath A; Su Y; Strongin AY; Cosford ND Bioorg Med Chem Lett; 2009 Oct; 19(19):5773-7. PubMed ID: 19703770 [TBL] [Abstract][Full Text] [Related]
20. The GA-Hecate Peptide inhibits the ZIKV Replicative Cycle in Different Steps and can Inhibit the Flavivirus NS2B-NS3 Protease after Cell Infection. da Silva Sanches PR; de Campos Faria JCE; Bittar C; Guberovich Olivieri HAS; de Moraes Roso Mesquita NC; Noske GD; de Godoy AS; Oliva G; Rahal P; Cilli EM Protein Pept Lett; 2024; 31(7):532-543. PubMed ID: 39039677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]